MorphoSys to Present Data on Proprietary Programs at American Society of Hematology Annual Meeting
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys to Present Data on Proprietary Programs at American Society of
Hematology Annual Meeting
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Abstracts Include Preliminary Safety and Efficacy Data for MOR208 in NHL
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced the
publication of three MorphoSys abstracts which were submitted to the 56th
American Society of Hematology (ASH) Annual Meeting and Exposition to take place
on December 6-9 in San Francisco, California. These abstracts include first
clinical data on the Company's proprietary drug candidate MOR208 from a Phase
2a study in patients with Non-Hodgkin's Lymphoma (NHL) and final data from the
Phase 1/2a clinical trial in Chronic Lymphocytic Leukemia (CLL). Additionally,
preclinical data became publicly available today demonstrating the synergistic
potential of the anti-CD38 antibody MOR202 and pomalidomide, a newly approved
immunomodulatory agent in multiple myeloma therapy.
"We are delighted to publish this substantial package of clinical and
preclinical data providing further validation for our lead cancer compounds
MOR208 and MOR202. For MOR208, we are in particular looking forward to
presenting first results for the Phase 2a study in NHL and the presentation of
final results for the Phase 1/2a trial in CLL from our collaborators Ohio State
University and Xencor at this year's ASH meeting in December," commented Dr.
Arndt Schottelius, Chief Development Officer of MorphoSys AG.
List of All Abstracts:
A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-
Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell
Non-Hodgkin's Lymphoma
Final Results and Follow-up of a Phase I Study of the Fc Engineered CD19
Antibody XmAb®5574 (aka MOR00208) in Patients with Relapsed or Refractory
Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Synergistic in vitro Activity of MOR202, a Fully Human CD38 Antibody, in
Combination with Pomalidomide
The full abstract can be accessed online at www.hematology.org/Meetings/Annual-
Meeting and http://bloodjournal.hematologylibrary.org/.
A research paper presenting and discussing the results of the Phase I Study of
MOR208 in CLL/SLL was recently published in the online issue of the peer-
reviewed medical journal BLOOD:
http://www.bloodjournal.org/content/early/2014/10/09/blood-2014-08-593269
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Specialist Corporate Communications & IR
Jessica Rush
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1869280/657224.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1869280]
Unternehmensinformation / Kurzprofil:
Datum: 06.11.2014 - 15:13 Uhr
Sprache: Deutsch
News-ID 350433
Anzahl Zeichen: 5692
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 146 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys to Present Data on Proprietary Programs at American Society of Hematology Annual Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
